BioWorld

March 1, 2010

IPO Activity Poised to Pop with Anthera, Aveo and Trius on Deck

It's been nearly a month since Ironwood Pharmaceuticals Inc. tested the biotech initial public offering waters, and now three more biotechs are queued up to price IPOs over the next three weeks. (BioWorld Today) Read More

HCV Combo Approach Keeping Partner Hopes Bright for Idenix

'Clear and Testable Hypothesis' on Pediatric Asthma's Roots

Amicus Adds $18.5M Publicly for Phase III Amigal Program

Collins: NIH Funding Boosts Economy, Spurs Job Growth

Move Over, Cerezyme; Shire's Vpriv Gets Official FDA Nod

Other News To Note

Vital Signs for March 1, 2010

Clinic Roundup

Bench Press

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...